Role of adipokines in complications related to obesity. A review

Advances in Medical Sciences

Volumn 54, Issue 2, 2009, Pages 150-157

  Gnacinska M ^a   Malgorzewicz S ^a   Stojek, M ^a   Lysiak Szydlowska W ^a   Sworczak, K ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Adipokines; Metabolic complications; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; BODY FAT; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ENDOCRINE FUNCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT;

ADIPOCYTES, WHITE; ADIPOKINES; ADIPONECTIN; HUMANS; INSULIN RESISTANCE; LEPTIN; OBESITY; RESISTIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74949135153     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-009-0035-2     Document Type: Review

References (67)

1. Pudel V, Ellrott T. Social and political aspects of adiposis [In German]. Chirurg. 2005 Jul;76(7):639-646
2. Reincke M. Adiposis and Internal Medicine [In German]. Internist (Berl). 2006 Mar; 47 (3):109-111
3. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a World Health Organization Consultation on Obesity. WHO Obesity Technical Report Series, No.894. Geneva, Switzerland: World Health Organization, 2000.p.256.
4. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocriol Metab. 2000 Oct; 10 (8): 327-332
5. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun; 89 (6): 2548-2556
6. Fischer-Posovszky P, Wabitsch M. Entwicklung und Funktion des Fettgewebes. Monatsschr Kinderheilkd. 2004 Sep; 152 (6): 834-842
7. Trayhurn P. Adipocyte biology. Obes Rev. 2007 Mar; 8 (Suppl.1): 41-44
8. Dieterle C, Landgraf R.Comorbidities and complications of adiposis [In German]. Internist (Berl). 2006 Feb;47(2):141-149
9. Deedwania PC, Volkova N. Current Treatment Options for the Metabolic Syndrome. Curr Treat Options Cardiovasc Med. 2005 May 7(1): 61-74.
10. Hanefeld M, Schaper F, Ceriello A. History and definition(s) of metabolic syndrome [In German]. Internist (Berl). 2007 Mar; 48:107-125
11. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome - an interplay of obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007 May; 9 (3): 218-232
12. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008 Feb;114(1):71-83.
13. Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med. 2001 Aug; 250 (2): 105-120
14. Hanefeld M, Ceriello A, Schwarz PE, Bornstein SR. The challenge of the Metabolic Syndrome.Horm Metab Res. 2007 Sep;39 (9):625-626
15. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand. 2005 Aug; 184(4): 285-293 (Pubitemid 41039735)
16. Vettor R, Milan G, Rossato M . Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther. 2005 Nov; 22 (Suppl 2): 3-10.
17. Schäffler A, Müller-Ladner U, Schölmerich , Büchler C . Role of Adipose Tissue as an Inflammatory Organ in Human Diseases. Endocr Rev. 2006 Aug; 27 (5): 449-467
18. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006, Oct; 6 (10): 772-783
19. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005 May; 115: 95): 1111-1119
20. Ronti T, Lupattelli G, Monnarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol. 2006 Sep-Oct; 64: 355-365
21. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and Insulin Resistance. J Clin Endocrinol Metab. 2004 Feb; 89 (2): 447-452
22. Drzewoski J. Podrçzny Leksykon Diabetologiczny. Warszawa: Delta Agencja Wydawnicza, 2005; 63.
23. You T, Nicklas BJ, Ding J, Penninx BW, Goodpaster BH, Bauer DC, Tylavsky FA, Harris TB, Kritchevsky SB.The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity.J Gerontol A Biol Sci Med Sci. 2008 Apr; 63(4):414-419
24. Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol. 2006 Jan; 186: 5-16.
25. Hahn S, Tan S, Janssen OE. Leptin. Neuroendocrine Wirkung und Einflüsse auf den menstruallen Zyklus. Gynecol Endocrinol. 2006 Feb; 4 (1): 33-38
26. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 1998;395 (6704):763-770
27. Friedman JM: The alphabet of weight control. Nature.1997;385(6549):119- 120
28. Lönnqvist F, Nordfors L, Schalling M. Leptin and its potential role in human obesity. J Intern Med. 1999 Jun; 245(6): 643-652
29. Al-Daghri N, Bartlett WA, Jones AF . Role of leptin in glucose metabolism in type 2 diabetes. Diabetes Obes Metab. 2002 May; 4(3): 147-155
30. Ceddia RB. Direct metabolic regulation in skeletal muscle and fat tissue by leptin: implications for glucose and fatty acids homeostasis. Int J Obes. 2005 Oct; 29(8): 1075-1083
31. Walczewska A. Leptyna-nowy hormon. Endokrynol Pol. 2000 Maj; 51(supl 1): 125-148
32. Carlsson B, Lindell K, Gabrielsson B. Obese (ob) gene defects are rare in human obesity. Obes Res. 1997Jan; 5 (1): 30-35
33. Howard JK, Cave BJ, Oksanen LJ, Tzameli L, Bjorbaek C, Flier JS. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haplinsufficiency of Socs3. Nat Med 2004;10(10):734-738
34. Havel PJ. Update on adipocyte hormones. Diabetes. 2004 Feb; 53: 143-151
35. Frühbeck G, Salvador J. Relation between leptin and the regulation of glucose metabolism. Diabetologia. 2000 Jan; 43(1): 3-12.
36. Moran O, Phillip M. Leptin: obesity, diabetes and other peripheral effects - a review. Pediatr Diabetes. 2003 Jun; 4(2): 101-109
37. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005 Feb; 6(1): 13-21.
38. Sharma AM, Tarnopolsky MA. Regulating adiponectin: of flax and flux. Diabetologia. 2005a, Jun; 48(6): 1035-1037
39. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Int Med. 2005 Feb; 257(2): 167-175
40. Funahashi T, Matsuzawa Y, Kihara S. Adiponectin as a potential key player in metabolic systeme. Insights into atherosclerosis, diabetes and cancer. Proceedings of the 13th International Atherosclerosis Symposium .International Congress Series 2004 May; 1262: 368-371
41. Kadowaki T, Yamauchi T, Kubota N . Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006 Jan; 106(1): 1784-1792
42. Targher G, Bertolini L, Scala L. Decreased plasma adiponectin contractions are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol. 2004 Dec; 61(6): 700-703
43. Frystyk J, Berne C, Berglund L . Jensevik K, Flyvbjerg A, Zethelius B. Serum Adiponectin Is a Predictor of Coronary Heart Disease: A Population-Based 10-Year Follow-Up Study in Elderly Men. J Clin Endocrinol Metab. 2007 Feb; 92(1): 2571-2576
44. Hara K, Yamauchi T, Imai Y, Manabe I, Nagai R, Kadowaki T. Reduced Adiponectin Level Is Associated With Severity of Coronary Artery Disease. Int Heart J. 2007 Mar; 48 (2): 149-153
45. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002 Jul;360(9236):7-58.
46. Zanetti M., Barazzoni R., Guarinieri G. Inflammation and Insulin Resistance in Uremia. J Ren Nutr 2008 Jan; 18 (1):70-76
47. Sharma AM, Chetty VT. Obesity, hypertension and insulin resistance. Acta Diabetol. 2005b Apr; 42: S3-S8.
48. Adeghate E. An update on the biology and physiology of resistin. Cell Mol Life Sci. 2004 Oct; 61(19-20): 2485-2496
49. Steppan CM, Lazar MA. The current biology of resistin. J Int Med. 2004 Apr; 255: 439-447
50. Osawa H,Onuma H, Ochi M, Murakami A, Yamauchi J, Takasuka T.Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun 2005;335(2):596-602.
51. Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol. 2006 Jan; 186: 5-16.
52. McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol. 2006 Apr; 17(2): 170-175
53. Hotamisligil GS, Arner P, Caro J. Increased adipose tissue expression of tumor necrosis factor-alpha in human obeity and insulin resistance. J Clin Invest. 1995 May; 95 (5): 2409-2415
54. lédziewski A, Kinalski M, Terlikowski S. Wpýw cytokin TNF-alfa na metabolizm tkanki t̃uszczowej. Post̃py Biologii Komórki. 2003 Maj; 30: 405-418
55. Wassink AM, Olijhoek JK, Visseran FLJ. The metabolic syndrome: metabolic changes with vascular consequences. Eur J Clin Invest. 2007 Jan; 37(1): 8-17.
56. Bogdáski P, Pupek-Musialik D, üczak M. Czynnik martwicy nowotworów (TNF-alpha) w procesie indukcji insulinoopornóci u osób z otýöcí prost̃. Diabetologia Döwiadczalna i Kliniczna. 2002; 6 (2): 449-454
57. Xu H, Barnes GT, Yang Q . Chronic inflammation in fat plays a crucial role in development of obesity-related insulin resistance. J Clin Invest. 2003 Dec; 102(6): 1821-1830
58. Pupek-Musialik D, Bogdáski P. Rola adiponektyny i czynnika martwicy nowotworów (TNF-alfa) w patogenezie nadcínienia t̃tniczego zwízanego z otýócí. Post̃py Nauk Medycznych. 2004 Kwiecië 17(4): 12-19
59. Scott DL, Kingsley GH. Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis. Engl J Med. 2006 Aug;355(3): 704-712
60. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 Induces Cellular Insulin Resistance in Hepatocytes. Diabetes. 2002 Dec;51(12): 3391-3399
61. Yeh ETH, Palusinski RP. C-reactive protein: the pawn has been promoted to queen. Curr Atheroscler Rep. 2003a Mar; 5(2): 101-105
62. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003 Jun;101(12): 1805-1812
63. Ridker PM. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem. 2009 Feb;55(2):209-215
64. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrynolytic system. Obes Rev. 2002 May; 3 (2): 85-101.
65. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc Aug; 2001, 60(2): 341-347
66. Trost S, Pratley R, Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep. 2006 Feb; 6(1): 47-54 .
67. Mavri A, Alessi MC, Juhan-Vague I. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular disease. J Intern Med. 2004 Apr; 255(4): 448-456